LitAlert ~~ GeneLit.com

    • Cell Cycle Checkpoints and Beyond: Exploiting the ATR/CHK1/WEE1 Pathway for the Treatment of PARP Inhibitor-Resistant Cancer.
    • Gupta N, Huang TT, Horibata S, Lee JM.
    • Pharmacol Res. 2022 Mar 5 [2022 Apr]:106162. doi: 10.1016/j.phrs.2022.106162. Epub ahead of print.
    • Review
    • Inhibitors of PARP: Number crunching and structure gazing.
    • Rudolph J, Jung K, Luger K.
    • Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2121979119. doi: 10.1073/pnas.2121979119. Epub 2022 Mar 8.
    • BRCA2 promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms.
    • Yang C, Zhang Q, Tang X, Wang B, Guan M, Tang G, Wu Z.
    • Epigenomics. 2022 Mar 9. doi: 10.2217/epi-2022-0025. Epub ahead of print.
    • Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.
    • Scott A, Mohan A, Austin S, Amini E, Raupp S, Pannecouk B, Kelley MJ, Narla G, Ramnath N.
    • JCO Oncol Pract. 2022 Mar 8:OP2100693. doi: 10.1200/OP.21.00693. Epub ahead of print.